X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NM5072 is currently an Orphan Drug Designated, investigational drug that selectively binds to Properdin, a protein of the AP. Blocking Properdin function is expected to block the lysis of PNH RBCs, thus treating the pathology of PNH
Lead Product(s): NM5072
Therapeutic Area: Rare Diseases and Disorders Product Name: NM5072
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2024
Details:
NM8074 (ruxoprubart) is an alternative pathway (AP) blocker anti-Bb antibody. It is being evaluated for the treatment of paroxysmal nocturnal hemoglobinuria.
Lead Product(s): Ruxoprubart
Therapeutic Area: Rare Diseases and Disorders Product Name: NM8074
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2024
Details:
NM8074 (ruxoprubart) is a novel Factor B binder, which is under phase 2 clinical development for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
Lead Product(s): Ruxoprubart
Therapeutic Area: Rare Diseases and Disorders Product Name: NM8074
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
NM3086 is an anti-P humanized monoclonal antibody that binds properdin with high affinity. NM3086 blocks both C3b and membrane-attack complex (MAC) formation, which being invetigated for for PNH patients.
Lead Product(s): NM3086
Therapeutic Area: Rare Diseases and Disorders Product Name: NM3086
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Details:
NM3086 selectively binds properdin and blocks the AP activation. As a result, the formation of C3 and C5 convertases is blocked, C3 and C5 are potent inflammation-causing agents which activate a variety of cells, which damages cells and tissues.
Lead Product(s): NM3086
Therapeutic Area: Ophthalmology Product Name: NM3086
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2023
Details:
NM8074 is a humanized monoclonal antibody that binds Bb, the catalytic domain of Factor B, and selectively blocks the initiation and propagation of the alternative pathway (AP). Treatment with NM8074 would selectively target the AP while leaving the CP pathway intact.
Lead Product(s): NM8074
Therapeutic Area: Rare Diseases and Disorders Product Name: NM8074
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2023
Details:
NM3086 (an anti-properdin antibody) blocks the alternative pathway without blocking the classical pathway and as a result a) blocks hemolysis of PNH-like erythrocytes, b) reduces lactate dehydrogenase, and c) reduces free hemoglobin (Hb) in an animal model of PNH.
Lead Product(s): NM3086
Therapeutic Area: Rare Diseases and Disorders Product Name: NM3086
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
NM8074 functions by binding Bb and selectively blocking the alternative pathway by neutralizing the activity of C3 convertase and C5 convertase, the two powerful proteases of the alternative pathway (AP).
Lead Product(s): NM8074
Therapeutic Area: Nephrology Product Name: NM8074
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2022
Details:
NM8074 is expected to be therapeutically effective across a broad range of rare and common complement-mediated diseases, including hemolytic disorders, renal disorders, ocular disorders, neurological disorders, and inflammatory disorders.
Lead Product(s): NM8074
Therapeutic Area: Hematology Product Name: NM8074
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
